Research progress on non-protein-targeted drugs for cancer therapy

Non-protein target drugs, especially RNA-based gene therapies for treating hereditary diseases, have been recognized worldwide. As cancer is an insurmountable challenge, no miracle drug is currently available. With the advancements in the field of biopharmaceuticals, research on cancer therapy has gradually focused on non-protein target-targeted drugs, especially RNA therapeutics, including oligonucleotide drugs and mRNA vaccines. This review mainly summarizes the clinical research progress in RNA therapeutics and highlights that appropriate target selection and optimized delivery vehicles are key factors in increasing the effectiveness of cancer treatment in vivo.

Automated summary

Non-protein target drugs, especially RNA-based gene therapies, have gained global recognition for treating hereditary diseases. However, there is a lack of miracle drugs for cancer, which remains a challenging condition. As biopharmaceutical research advances, the focus of cancer therapy has shifted towards non-protein targets, particularly RNA therapeutics such as oligonucleotide drugs and mRNA vaccines. This review provides a summary of the clinical research progress in RNA therapeutics, emphasizing the importance of appropriate target selection and optimized delivery vehicles in enhancing the effectiveness of cancer treatment in vivo.